Citeline

Last year was pharma’s second-hottest ever in terms of new active substances (NASs) introduced to market. While the forecast for NAS launches is generally fair, there are a few clouds on the horizon in terms of a high Phase II failure rate and a small number of first-in-class drugs launched in 2023. Explore the detailed statistics on NASs in our latest infographic and delve deeper into the comprehensive report available here: https://ow.ly/ebRY50RmNFz #PharmaTrends #DrugDevelopment #BiopharmaInsights #PharmaIndustry #PharmaStatistics

Trial Summaries is designed to be a centralized, non-promotional location for clinical trial information, which is why AstraZeneca decided to host its studies and summaries there. Explore our case study to see why Trial Summaries checked all the boxes for AstraZeneca! Learn more: https://ow.ly/k7u350RBI3A #ClinicalTrialInfo #TrialSummaries #HealthcareData #ClinicalResearch

#Medtech Insight is writing a special series honoring May and June awareness months for #mentalhealth. My first story is a feature on Motif Neurotech where I spoke with its CEO Jacob Robinson about its BCI technology targeting depression. Citeline Commercial #mentalhealth #depression #healthcare #TMS #brain #BCI #brainhealth #medtech #AI #digitalhealth Ryan Nelson Brian Bossetta

GLP-1s have been the unmatched pharma success story over the past two years. Its development promises to improve the health of millions of patients and reshape the broader industry, from portfolios to pricing and deal-making to demonstration of value. Our latest blog contains excerpts from subject matter experts across Norstella, who have each weighed in on the latest developments in this must-watch space. Look for expert opinions from Citeline, MMIT (Managed Markets Insight & Technology), Panalgo, and the latest market forecasts from Evaluate Ltd. Read the article here: https://ow.ly/6MNJ50RfoVA Daniel Chancellor, Jeffrey Stevens, Kevin Grogan, Margaret (Meg) Richards, PhD, MPH, Grace Casaschi, Jacquelyn Cafasso, Tim Blackstock #GLP1 #Pharma #PharmaIndustry

One of the more important articles I've written. This novel therapy shows tremendous promise in treating depression, especially for adolescents. As Chrissy says, it could save lives. It did hers. Citeline

🔎 Panorama France HealthTech 2023 🔎   EN : This is it! The English version of our annual industry report ‘Panorama France HealthTech’ is now available for download! >> Download the report: https://lnkd.in/eqEzqqaD   ✔ Cowritten with our partners Banque Populaire, Bpifrance, Citeline, Euronext and EY, this report features key insights into the life sciences industry in 2023/2024. Discover the latest trends for the biotech, medtech and digital health industries in France! This report includes: ➡ Companies’ key facts & figures: revenues, R&D expenses, areas of development, international presence ➡ R&D trends ➡ Market access strategies ➡ Funding of the industry (USA, Europe, and France) including public support through grants and equity funding: seed, VC and financial markets ➡ A focus on rare diseases research in Europe ➡ Incentives and fiscal schemes for R&D in France ➡ Interviews with CEOs of key companies showcasing their innovation and milestones ➡ And much more Now available in digital format on our website, the 'Panorama France HealthTech' is an essential annual benchmark for life sciences start-ups and SMEs! ______________________________________________________________________________ FR: 🔎 Panorama France HealthTech 2023 🔎   La version anglaise du rapport annuel de @France Biotech , 'Panorama France HealthTech', est maintenant disponible ! >> https://lnkd.in/eqEzqqaD ✔ Rédigé en collaboration avec nos partenaires Banque Populaire, Bpifrance, Citeline, Euronext et EY, il offre un aperçu complet de l'écosystème HealthTech français ! A retrouver : ➡ Les chiffres clés des entreprises : chiffre d'affaires, dépenses de R&D, aires thérapeutiques, présence internationale ➡ Les tendances en R&D ➡ Les stratégies d'accès au marché ➡ Le financement de l'industrie (États-Unis, Europe et France), y compris le soutien public par le biais de subventions et en capital : amorçage, capital-risque et marchés financiers ➡ La recherche sur les maladies rares en Europe ➡ Des interviews avec des dirigeants de HealthTech ➡ La présentation des dispositifs fiscaux pour la R&D en France Désormais disponible en format numérique sur notre site web, le 'Panorama France HealthTech' est une référence annuelle essentielle pour les start-ups et PME françaises travaillant dans les technologies de santé innovantes ! Rosalie MAURISSE Beatrice De Keukeleire Cedric Garcia Sarah Ankri Alexis JANIN Ismail El khalloufi Aurelie Girod Jean-Marc Mezin Emilie Moussin Daniel Chancellor Marianne Vergnes Olivier Chabanon Franck Mouthon Chloe Evans Cédric Dechaud

It's webinar season at Norstella and we are hosting several open events to talk through our recent research reports and views of the industry. No speaking duties for me, but having seen snippets from each then I'm looking forward to making myself comfortable in the audience. Great opportunities to stay abreast of industry trends – whether your focus is in drug development, market access, or somewhere in between – and to get closer to the subject matter experts behind our brands. 💡 Pharma R&D Annual Review: May 21, 3pm BST/10am ET Ian Lloyd and Alexandra Shimmings, both of Citeline, continue their long-standing double act in reviewing the latest global R&D trends. Pipelines, approvals, emerging modalities, therapeutic areas, drug targets, leading sponsors, geographic hotspots and more - if you've seen any of the previous editions then you know not to miss this. https://lnkd.in/efECkPtd 💡 Overcoming the Barriers to Patient Access in 2024 and Beyond: May 21, 7pm BST/2pm ET If you are more focused on the latest commercial dynamics, then join Dinesh Kannan Kabaleeswaran and Jennifer (Goldenberg) Klarer, M.Sc.Eng. in this review of the latest patient access themes. MMIT (Managed Markets Insight & Technology) and The Dedham Group joined forces earlier in the year for a quantitative stakeholder survey, and this is our exclusive take on the results and implications for patient access, from pharma to payers and providers. https://lnkd.in/eTkwBerh 💡 Orphan Drugs - Are They Losing Their Sparkle: May 29, 3pm BST/10am ET Puru Gaur will give the lowdown from Evaluate Ltd's latest orphan drug deep dive, with Melanie Senior and Stephanie Leouzon debating the implications of an apparent slow down in sales growth. Does this indicate a drop in investor and pharma appetite for rare diseases, or is it just a case of maturity. And how do new technologies and legislation affect the balance? Join us to find out. https://lnkd.in/e_he3TQu

Two months to enter the Awards! Have you started your entries to the Citeline Japan Awards 2024? Don't miss out on the opportunity to gain recognition for your contributions, showcase your achievements, and network with industry leaders from across Japan. The entry deadline is Monday, July 15, 2024. #CitelineJapanAwards #LifeSciences #Innovation #Japan #Awards #Recognition #Networking https://ow.ly/bcUJ50RAip3

Introducing Citeline’s Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape. Global Patient Insights integrates RWD on patient population and diversity with Sitetrove’s best-in-class intelligence to optimize the site selection process for clinical trial sponsors. Read today’s announcement: https://ow.ly/vu8s50RIhoW. #PatientInsights #HealthcareData #ClinicalResearch #PatientDiversity #GlobalPatientInsights #ClinicalTrials #TrialSites #SiteSelection #RWD

Introducing Citeline’s Global Patient Insights, the industry’s most comprehensive view of the worldwide patient landscape. Global Patient Insights integrates RWD on patient population and diversity with Sitetrove’s best-in-class intelligence to optimize the site selection process for clinical trial sponsors. Read today’s announcement: https://ow.ly/XVPu50RFPnt. #PatientInsights #HealthcareData #ClinicalResearch #PatientDiversity #GlobalPatientInsights #ClinicalTrials #TrialSites #SiteSelection #RWD